Oncology Central

New drug shown to boost response to radiotherapy in patients

Results from the experimental study US NCI trial #9882 have suggested that the new drug ropidoxuridine, or 5-iodo-2-pyrimadinone-2’-deoxribose (IPdR), increases patient response to radiotherapy with few side effects.

The research, presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (13–16 November, Dublin, Ireland), states that the drug changes into its active form when it enters the body and makes cancerous cells more susceptible to radiotherapy treatment.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.